UBS Upgrades Corcept Therapeutics to Buy, Raises Price Target to $72

Benzinga Newsdesk www.benzinga.com Positive 90.9%

Neg 0% Neu 0% Pos 90.9%

UBS analyst Ashwani Verma upgrades Corcept Therapeutics (NASDAQ:CORT) from Neutral to Buy and raises the price target from $44 to $72.